What is the recommended intravenous therapy for a term or near‑term newborn with echocardiographically confirmed persistent pulmonary hypertension and an oxygenation index greater than 25 when inhaled nitric oxide (iNO) is unavailable?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Intravenous Milrinone is the Recommended Therapy

When inhaled nitric oxide (iNO) is unavailable for a term or near-term newborn with echocardiographically confirmed PPHN and an oxygenation index greater than 25, intravenous milrinone is the most reasonable intravenous therapy based on current guidelines. 1

Guideline-Based Recommendation

The 2015 AHA/ATS Pediatric Pulmonary Hypertension Guidelines specifically address this scenario and state that intravenous milrinone is reasonable in infants with PPHN and signs of left ventricular (LV) dysfunction (Class IIa; Level of Evidence B) 1. While the guideline frames this recommendation around LV dysfunction, this is particularly relevant because:

  • Many infants with severe PPHN (OI >25) have concurrent cardiac dysfunction
  • Milrinone provides both pulmonary vasodilation AND inotropic support
  • It works through a nitric oxide-independent mechanism, making it suitable when iNO is unavailable

Why Milrinone Over Other Options

The guidelines also mention sildenafil and inhaled prostacyclin analogs, but these are specifically recommended as adjunctive therapy for infants refractory to iNO 1—meaning they're positioned as add-ons when iNO fails, not as primary alternatives when iNO is unavailable.

Milrinone's advantages in this context:

  • Rapid onset: Research shows significant OI reduction within 24 hours of initiation 2
  • Dual mechanism: Provides pulmonary vasodilation plus cardiac inotropic support 2
  • Proven efficacy: In neonates with severe PPHN (OI >20) who failed iNO, milrinone reduced OI from 28.1 to 8.0 within 24 hours (P < .001) 2
  • Hemodynamic stability: Does not cause systemic hypotension; actually trends toward improved blood pressure 2

Practical Implementation Algorithm

Starting milrinone when iNO is unavailable:

  1. Confirm diagnosis: Echocardiographic evidence of PPHN with right-to-left shunting
  2. Assess cardiac function: Look specifically for LV dysfunction on echo (strengthens indication)
  3. Loading dose: Consider 50 mcg/kg over 30-60 minutes (though some centers omit this to avoid hypotension)
  4. Maintenance infusion: Start at 0.33-0.5 mcg/kg/min
  5. Monitor closely: Blood pressure, heart rate, oxygenation every 15-30 minutes initially
  6. Titrate: Can increase to 0.75-1.0 mcg/kg/min based on response
  7. Expect response: Should see OI improvement within 4-24 hours 2

Critical Caveats and Monitoring

Watch for hypotension: While less common than with other vasodilators, dose adjustment or brief vasoactive support may be needed 3. This is manageable and should not deter use.

Extremely preterm infants: Exercise particular caution in very preterm neonates (<28 weeks), as milrinone's vasodilatory effects may increase risk of intraventricular hemorrhage 3. However, your patient is term/near-term, so this is less concerning.

Platelet effects: Milrinone has mild antiplatelet properties—monitor for bleeding, especially if coagulopathy present 3.

Alternative Considerations

If milrinone is also unavailable or contraindicated:

  • Intravenous sildenafil: Demonstrated safety and efficacy in PPHN with OI >15, with significant OI improvement within 4 hours 4. However, this requires careful dose escalation and monitoring.
  • Intravenous epoprostenol (prostacyclin): Shows rapid OI reduction in iNO-refractory cases 5, but requires specialized delivery systems and has higher risk of systemic hypotension.

The Bottom Line

Intravenous milrinone is your best option when iNO is unavailable for severe PPHN (OI >25). It has the strongest guideline support as a standalone therapy (Class IIa), works through a complementary mechanism, provides both pulmonary and cardiac benefits, and has demonstrated clinical efficacy in this exact population. Start at 0.33-0.5 mcg/kg/min after confirming the diagnosis with echocardiography, monitor hemodynamics closely, and expect oxygenation improvement within 24 hours. If the infant fails to respond or deteriorates, prepare for ECMO transfer, as this is indicated for severe PH refractory to medical management 1.

Related Questions

How should a hypotensive neonate with persistent pulmonary hypertension be managed when three inotropes are required?
In a newborn with persistent pulmonary hypertension of the newborn (PPHN) who is receiving inhaled nitric oxide (iNO) and has an oxygenation index >25 despite optimal ventilation, when is intravenous sildenafil indicated and what dosing regimen should be used?
In acute pulmonary hypertension, should inhaled nitric oxide be used instead of vasopressin as first‑line therapy?
What is the mechanism of action of milrinone in treating persistent pulmonary hypertension of the newborn (PPHN)?
When should milrinone be discontinued?
What is the appropriate resuscitation protocol for a hypothermic patient, including chest compressions, defibrillation, epinephrine administration, and rewarming methods?
What is the appropriate dosing and administration of intravenous sildenafil for a newborn with persistent pulmonary hypertension of the newborn?
In a newborn with persistent pulmonary hypertension of the newborn (PPHN) who is receiving inhaled nitric oxide (iNO) and has an oxygenation index >25 despite optimal ventilation, when is intravenous sildenafil indicated and what dosing regimen should be used?
How should I counsel a patient on proper use of the Spiriva Respimat (tiotropium bromide) inhaler?
Can multiple sclerosis cause an elevated D-dimer level?
What is the appropriate vitamin D3 (cholecalciferol) dosing for an adolescent with severe vitamin D deficiency (25‑hydroxy vitamin D 9 ng/mL) and normal calcium stores?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.